{"nctId":"NCT00534248","briefTitle":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","startDateStruct":{"date":"2007-10"},"conditions":["Shingles"],"count":22439,"armGroups":[{"label":"Zostavax™","type":"EXPERIMENTAL","interventionNames":["Biological: Zoster Vaccine, Live (Zostavax™)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Comparator: Placebo"]}],"interventions":[{"name":"Zoster Vaccine, Live (Zostavax™)","otherNames":["V211","Zostavax™"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be between 50 - 59 years of age\n* No fever on day of vaccination\n* Females of reproductive potential must be willing to use acceptable form of birth control\n\nExclusion Criteria:\n\n* Have received chicken pox or shingles vaccine\n* Have already had shingles\n* Have recently had another vaccination\n* Pregnant or breast feeding. Have participated in another research study in the last 30 days\n* You are taking certain antiviral drugs\n* History of allergic reaction to any vaccine component, including gelatin or neomycin","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"59 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group","description":"Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.994","spread":null},{"groupId":"OG001","value":"6.596","spread":null}]}]}]},{"type":"SECONDARY","title":"Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group","description":"VZV antibody response as measured by Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) in the group that received Zostavax™ compared with the group that received placebo, based on the random subcohort population.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"660.0","spread":null},{"groupId":"OG001","value":"293.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period","description":"A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing\n\nhospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":243,"n":11094},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Headache","Injection site pruritus"]}}}